CD45 Antibody Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    BioLegend cd45
    Cancer-derived SORBS2-stabilized secretome suppresses tumor metastasis and recruitment of tumor-supportive infiltrates in vivo. a The percentage of CD11b + GR-1+ cells in the <t>CD45+</t> cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and WFDC1 overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. b The percentage of CD11b + GR-1+ cells in the CD45+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and IL-17D-overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. c The percentage of CD206+ cells in the CD11b + GR-1+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and WFDC1-overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. d The percentage of CD206+ cells in the CD11b + GR-1+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and IL-17D-overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. e At the global level, SORBS2 could bind different kinds of mRNAs and stabilize a proportion of these mRNAs. The net effect of progression-promoting and -inhibiting alterations determine whether SORBS2 loss is beneficial for ovarian cancer metastatic colonization. f At the target mRNA level, SORBS2 could stabilize the transcripts of WFDC1 and IL-17D, which leads to overexpression of these secreting factors. On one hand, they could partly suppress ovarian cancer metastasis; on the other hand, they could inhibit the polarization of monocytes towards MDSCs and M2-like macrophages, which is important for a immune suppressive tumor microenvironment favorable for ovarian cancer metastatic colonization. Data are shown as mean ± SEM. * P
    Cd45, supplied by BioLegend, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd45/product/BioLegend
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd45 - by Bioz Stars, 2021-05
    99/100 stars
      Buy from Supplier

    99
    Thermo Fisher cd45
    Regulation of <t>CD45</t> + cell number by both MEK and Hh signaling pathways. ( A ) Representative immunofluorescent staining images of CD45 + cells in liver tissues after drug treatments. ( B ) Summary of A from 10 images in each group (from at least 3 mice) with the number of CD45 + cells per field under microscope (200×). ( C ) Summary of flow cytometry analysis of CD45+ cells in different treatment groups (from three mice/group). * indicates p
    Cd45, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd45/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd45 - by Bioz Stars, 2021-05
    99/100 stars
      Buy from Supplier

    99
    Thermo Fisher cd45 monoclonal antibody
    Identification of BMSCs. (A) BMSCs were negative for <t>CD45</t> (1.92%) and CD34 (7.21%) but positive for CD73 (88.54%), CD90 (98.82%) and CD105 (99.58%). (B) By seeding 1,000 cells in a 10 mm dish, BMSCs demonstrated the ability to form a visible colony unit as indicated by the arrows. (C) BMSCs exhibited the capacity to differentiate to (C-a) adipogenic cells, (C-b) osteogenic cells and (C-c) chondrocytes as indicated by the arrows. The corresponding staining results are presented in in (Cd-f), (C-d) adipogenic cells stained with oil red O, (C-e) osteogenic cells stained with alizarin red S and (C-f) chondrocytes stained with alcian blue are indicated by the arrows. (Cg-i) Negative controls were undifferentiated BMSCs respectively stained with (Cg) oil red O, (Ch) alizarin red S and (Ci) alcian blue which were indicated by the arrows. (D-a) HD-BMSCs and (D-b) CML-BMSCs at passage 3 exhibited fibroblast-like morphology as indicated by the arrows. (D-c) Certain HD-BMSCs at passage 5 grew excessively large and exhibited an irregular shape as indicated by the arrows. (D-d) Compared with HD-BMSCs, a higher number of CML-BMSCs at passage 5 grew excessively larger and exhibited an irregular shape as indicated by the arrows. Black lines represent 10 µm. Magnification, ×100. CON, control; BMSCs, bone mesenchymal stromal cells; HD, healthy donor; CML, chronic myelogenous leukemia.
    Cd45 Monoclonal Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd45 monoclonal antibody/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd45 monoclonal antibody - by Bioz Stars, 2021-05
    99/100 stars
      Buy from Supplier

    95
    BioLegend anti cd45
    Hypocretin controls pre-neutrophil CSF1 production in the bone marrow. Hypocretin receptor-1 ( Hcrtr1 ) mRNA in cells sorted from bone marrow (n=4 except neutrophils n=7). b , HcrtR1 mRNA expression in bone marrow and blood neutrophil populations (n=4). c , Flow cytometry plot of HCRTR1 + pre-neutrophils in the bone marrow of WT mice transplanted with HcrtR1 Gfp/Gfp BM. d , Colony stimulating factor-1 ( Csf1 ) expression in sorted bone marrow cells (for Ly-6C hi monocytes, B cells, and other leukocytes n=3; for neutrophils and <t>CD45</t> − cells n=5). e , Csf1 expression in sorted bone marrow neutrophil populations (n=4). f , CSF1 production by pre-neutrophils sorted from WT mice exposed to LPS and/or HCRT-1 (for untreated and HCRT-1 n=4 per group; for LPS and LPS+HCRT-1 n=6 per group) *p
    Anti Cd45, supplied by BioLegend, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd45/product/BioLegend
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti cd45 - by Bioz Stars, 2021-05
    95/100 stars
      Buy from Supplier

    N/A
    CD45 has been identified as a transmembrane glycoprotein broadly expressed among hematopoietic cells Multiple isoforms of CD45 are distributed throughout the immune system according to cell type These isoforms arise
      Buy from Supplier



    Image Search Results


    Cancer-derived SORBS2-stabilized secretome suppresses tumor metastasis and recruitment of tumor-supportive infiltrates in vivo. a The percentage of CD11b + GR-1+ cells in the CD45+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and WFDC1 overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. b The percentage of CD11b + GR-1+ cells in the CD45+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and IL-17D-overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. c The percentage of CD206+ cells in the CD11b + GR-1+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and WFDC1-overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. d The percentage of CD206+ cells in the CD11b + GR-1+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and IL-17D-overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. e At the global level, SORBS2 could bind different kinds of mRNAs and stabilize a proportion of these mRNAs. The net effect of progression-promoting and -inhibiting alterations determine whether SORBS2 loss is beneficial for ovarian cancer metastatic colonization. f At the target mRNA level, SORBS2 could stabilize the transcripts of WFDC1 and IL-17D, which leads to overexpression of these secreting factors. On one hand, they could partly suppress ovarian cancer metastasis; on the other hand, they could inhibit the polarization of monocytes towards MDSCs and M2-like macrophages, which is important for a immune suppressive tumor microenvironment favorable for ovarian cancer metastatic colonization. Data are shown as mean ± SEM. * P

    Journal: Genome Biology

    Article Title: The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts

    doi: 10.1186/s13059-018-1412-6

    Figure Lengend Snippet: Cancer-derived SORBS2-stabilized secretome suppresses tumor metastasis and recruitment of tumor-supportive infiltrates in vivo. a The percentage of CD11b + GR-1+ cells in the CD45+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and WFDC1 overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. b The percentage of CD11b + GR-1+ cells in the CD45+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and IL-17D-overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. c The percentage of CD206+ cells in the CD11b + GR-1+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and WFDC1-overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. d The percentage of CD206+ cells in the CD11b + GR-1+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and IL-17D-overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. e At the global level, SORBS2 could bind different kinds of mRNAs and stabilize a proportion of these mRNAs. The net effect of progression-promoting and -inhibiting alterations determine whether SORBS2 loss is beneficial for ovarian cancer metastatic colonization. f At the target mRNA level, SORBS2 could stabilize the transcripts of WFDC1 and IL-17D, which leads to overexpression of these secreting factors. On one hand, they could partly suppress ovarian cancer metastasis; on the other hand, they could inhibit the polarization of monocytes towards MDSCs and M2-like macrophages, which is important for a immune suppressive tumor microenvironment favorable for ovarian cancer metastatic colonization. Data are shown as mean ± SEM. * P

    Article Snippet: Antibodies used are as follows: SORBS2 (Abcam, ab73444), cleaved caspase 3 (Abcam, ab13847), WFDC1 (Abcam, ab126846, for western blotting analysis), WFDC1 (Sigma, HPA031411, for IHC analysis), IL-17D (Abcam, ab77185), Ki-67(Abcam, ab15580), Flag (Sigma, F3165), β-actin (Abcam, ab8226), HLA-DR (human; BD Bioscience, 556,643), CD14 (human; BD Bioscience, 555,397), CD206 (human; BioLegend, 321,121), CD45 (murine; BioLegend, 103,127), CD11b (murine; BioLegend, 101,230), GR-1 (murine; BioLegend, 108,416), CD206 (murine; BioLegend, 141,703).

    Techniques: Derivative Assay, In Vivo, Mouse Assay, Over Expression

    Regulation of CD45 + cell number by both MEK and Hh signaling pathways. ( A ) Representative immunofluorescent staining images of CD45 + cells in liver tissues after drug treatments. ( B ) Summary of A from 10 images in each group (from at least 3 mice) with the number of CD45 + cells per field under microscope (200×). ( C ) Summary of flow cytometry analysis of CD45+ cells in different treatment groups (from three mice/group). * indicates p

    Journal: Cancers

    Article Title: Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis

    doi: 10.3390/cancers10110403

    Figure Lengend Snippet: Regulation of CD45 + cell number by both MEK and Hh signaling pathways. ( A ) Representative immunofluorescent staining images of CD45 + cells in liver tissues after drug treatments. ( B ) Summary of A from 10 images in each group (from at least 3 mice) with the number of CD45 + cells per field under microscope (200×). ( C ) Summary of flow cytometry analysis of CD45+ cells in different treatment groups (from three mice/group). * indicates p

    Article Snippet: Five-micron paraffin-embedded sections were labeled with primary antibodies against phosphor-p44/p42 MAPK (Erk1/2) (Thr 202/Tyr 204) (Cell Signaling Technology Cat# 4370, 1:200, Danvers, MA, USA), Ki-67 (ab15580, 1:500, AbCam, Cambridge, MA, USA) and CD45 (14-0451, 1:100, eBioscience, San Diego, CA, USA).

    Techniques: Staining, Mouse Assay, Microscopy, Flow Cytometry, Cytometry

    Effects of MEK/Hh signaling inhibition on Ly6G + CD11b + cells in the metastatic liver tissues (MMC18-based model in immune competent C57/B6 mice). ( A ) Representative images of flow cytometry of CD45 + CD11b + Gr1 + cells in different liver tissues; ( B ) Cell population composition in metastatic liver tissues, and the number was the average from five mice/group; ( C ) Representative images of liver tissues with or without treatment of Ly6G neutralizing antibodies. While IgG treated mice had many metastatic nodules (indicated by purple arrowheads), Ly6G neutralizing antibody treatment led to no visible or only a few metastatic nodules; ( D ) Ly6G neutralizing antibody treatment led to reduced liver weight in MMC18- based mouse model (five mice/group), suggesting a reduced liver metastasis; ( E ) Similar results were obtained using Pan02 cells (five mice/group). Ly6G neutralizing antibody treatment led to reduced liver weight. * p values were calculated using Student t test of two independent means.

    Journal: Cancers

    Article Title: Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis

    doi: 10.3390/cancers10110403

    Figure Lengend Snippet: Effects of MEK/Hh signaling inhibition on Ly6G + CD11b + cells in the metastatic liver tissues (MMC18-based model in immune competent C57/B6 mice). ( A ) Representative images of flow cytometry of CD45 + CD11b + Gr1 + cells in different liver tissues; ( B ) Cell population composition in metastatic liver tissues, and the number was the average from five mice/group; ( C ) Representative images of liver tissues with or without treatment of Ly6G neutralizing antibodies. While IgG treated mice had many metastatic nodules (indicated by purple arrowheads), Ly6G neutralizing antibody treatment led to no visible or only a few metastatic nodules; ( D ) Ly6G neutralizing antibody treatment led to reduced liver weight in MMC18- based mouse model (five mice/group), suggesting a reduced liver metastasis; ( E ) Similar results were obtained using Pan02 cells (five mice/group). Ly6G neutralizing antibody treatment led to reduced liver weight. * p values were calculated using Student t test of two independent means.

    Article Snippet: Five-micron paraffin-embedded sections were labeled with primary antibodies against phosphor-p44/p42 MAPK (Erk1/2) (Thr 202/Tyr 204) (Cell Signaling Technology Cat# 4370, 1:200, Danvers, MA, USA), Ki-67 (ab15580, 1:500, AbCam, Cambridge, MA, USA) and CD45 (14-0451, 1:100, eBioscience, San Diego, CA, USA).

    Techniques: Inhibition, Mouse Assay, Flow Cytometry, Cytometry

    Identification of BMSCs. (A) BMSCs were negative for CD45 (1.92%) and CD34 (7.21%) but positive for CD73 (88.54%), CD90 (98.82%) and CD105 (99.58%). (B) By seeding 1,000 cells in a 10 mm dish, BMSCs demonstrated the ability to form a visible colony unit as indicated by the arrows. (C) BMSCs exhibited the capacity to differentiate to (C-a) adipogenic cells, (C-b) osteogenic cells and (C-c) chondrocytes as indicated by the arrows. The corresponding staining results are presented in in (Cd-f), (C-d) adipogenic cells stained with oil red O, (C-e) osteogenic cells stained with alizarin red S and (C-f) chondrocytes stained with alcian blue are indicated by the arrows. (Cg-i) Negative controls were undifferentiated BMSCs respectively stained with (Cg) oil red O, (Ch) alizarin red S and (Ci) alcian blue which were indicated by the arrows. (D-a) HD-BMSCs and (D-b) CML-BMSCs at passage 3 exhibited fibroblast-like morphology as indicated by the arrows. (D-c) Certain HD-BMSCs at passage 5 grew excessively large and exhibited an irregular shape as indicated by the arrows. (D-d) Compared with HD-BMSCs, a higher number of CML-BMSCs at passage 5 grew excessively larger and exhibited an irregular shape as indicated by the arrows. Black lines represent 10 µm. Magnification, ×100. CON, control; BMSCs, bone mesenchymal stromal cells; HD, healthy donor; CML, chronic myelogenous leukemia.

    Journal: Oncology Letters

    Article Title: Bone mesenchymal stromal cells exhibit functional inhibition but no chromosomal aberrations in chronic myelogenous leukemia

    doi: 10.3892/ol.2018.9681

    Figure Lengend Snippet: Identification of BMSCs. (A) BMSCs were negative for CD45 (1.92%) and CD34 (7.21%) but positive for CD73 (88.54%), CD90 (98.82%) and CD105 (99.58%). (B) By seeding 1,000 cells in a 10 mm dish, BMSCs demonstrated the ability to form a visible colony unit as indicated by the arrows. (C) BMSCs exhibited the capacity to differentiate to (C-a) adipogenic cells, (C-b) osteogenic cells and (C-c) chondrocytes as indicated by the arrows. The corresponding staining results are presented in in (Cd-f), (C-d) adipogenic cells stained with oil red O, (C-e) osteogenic cells stained with alizarin red S and (C-f) chondrocytes stained with alcian blue are indicated by the arrows. (Cg-i) Negative controls were undifferentiated BMSCs respectively stained with (Cg) oil red O, (Ch) alizarin red S and (Ci) alcian blue which were indicated by the arrows. (D-a) HD-BMSCs and (D-b) CML-BMSCs at passage 3 exhibited fibroblast-like morphology as indicated by the arrows. (D-c) Certain HD-BMSCs at passage 5 grew excessively large and exhibited an irregular shape as indicated by the arrows. (D-d) Compared with HD-BMSCs, a higher number of CML-BMSCs at passage 5 grew excessively larger and exhibited an irregular shape as indicated by the arrows. Black lines represent 10 µm. Magnification, ×100. CON, control; BMSCs, bone mesenchymal stromal cells; HD, healthy donor; CML, chronic myelogenous leukemia.

    Article Snippet: A total of six tubes were separately resuspended with 100 µl phosphate buffer solution (PBS) (Hyclone; GE Healthcare) and labeled with 5 µl monoclonal antibodies per 1×105 cells for 30 min in the dark at 4°C as follow: anti-CD45-phycoerythrin (PE) (12-0459-41), anti-CD34-PE (12-0349-41), anti-CD73-PE (12-0739-41), anti-CD90-PE (12-0909-41), anti-CD105-PE (12-1057-41) (all monoclonal antibodies 1:20 dilution, eBiosciences; Thermo Fisher Scientific Inc.).

    Techniques: Staining

    Hypocretin controls pre-neutrophil CSF1 production in the bone marrow. Hypocretin receptor-1 ( Hcrtr1 ) mRNA in cells sorted from bone marrow (n=4 except neutrophils n=7). b , HcrtR1 mRNA expression in bone marrow and blood neutrophil populations (n=4). c , Flow cytometry plot of HCRTR1 + pre-neutrophils in the bone marrow of WT mice transplanted with HcrtR1 Gfp/Gfp BM. d , Colony stimulating factor-1 ( Csf1 ) expression in sorted bone marrow cells (for Ly-6C hi monocytes, B cells, and other leukocytes n=3; for neutrophils and CD45 − cells n=5). e , Csf1 expression in sorted bone marrow neutrophil populations (n=4). f , CSF1 production by pre-neutrophils sorted from WT mice exposed to LPS and/or HCRT-1 (for untreated and HCRT-1 n=4 per group; for LPS and LPS+HCRT-1 n=6 per group) *p

    Journal: Nature

    Article Title: Sleep modulates hematopoiesis and protects against atherosclerosis

    doi: 10.1038/s41586-019-0948-2

    Figure Lengend Snippet: Hypocretin controls pre-neutrophil CSF1 production in the bone marrow. Hypocretin receptor-1 ( Hcrtr1 ) mRNA in cells sorted from bone marrow (n=4 except neutrophils n=7). b , HcrtR1 mRNA expression in bone marrow and blood neutrophil populations (n=4). c , Flow cytometry plot of HCRTR1 + pre-neutrophils in the bone marrow of WT mice transplanted with HcrtR1 Gfp/Gfp BM. d , Colony stimulating factor-1 ( Csf1 ) expression in sorted bone marrow cells (for Ly-6C hi monocytes, B cells, and other leukocytes n=3; for neutrophils and CD45 − cells n=5). e , Csf1 expression in sorted bone marrow neutrophil populations (n=4). f , CSF1 production by pre-neutrophils sorted from WT mice exposed to LPS and/or HCRT-1 (for untreated and HCRT-1 n=4 per group; for LPS and LPS+HCRT-1 n=6 per group) *p

    Article Snippet: The following monoclonal antibodies were used for flow cytometric analysis: anti-CD45 (BioLegend, clone30-F11, Cat#103147, Lot#B243834), anti-CD45.1 (BioLegend, clone A20, Cat#110708), anti-CD45.2 (BioLegend, clone 104, Cat#109802), anti-CD3 (BioLegend, clone 17A2, Cat#100206), anti-CD90.2 (BioLegend, clone 53–2.1, Cat#105308, Lot#B260050), anti-CD19 (BioLegend, clone 6D5, Cat#115508, Lot#B226581), anti-B220 (BD Biosciences, clone RA3–6B2, Cat#553089, Lot#6012954), anti-NK1.1 BioLegend, clone PK136, Cat#108708), anti-Ly6G (BioLegend, clone 1A8, Cat127614#, Lot#B259670), anti-Ly6C (BioLegend, AL-21, Cat#128006, Lot#B247728), anti-MHCII (BioLegend, clone M5/114.152, Cat#107602, Lot#B217859), anti-F4/80 (Biolegend, clone BM8, Cat#123114, Lot#B237342), anti-CD11b (BioLegend, clone M1/70, Cat#101226, Lot#B238268), anti-CD115 (BioLegend, clone AFS98, Cat#135517, Lot#B265220), anti-Ter119 (BioLegend, clone TER-119, Cat#116208, Lot#B220899), anti-CD34 (eBioscience, clone RAM34, Cat#11–0341-85, Lot#E00265–1634), anti-CD49b (BioLegend, clone DX5, Cat#1089008, Lot#B258302), ant-CD11c (BioLegend, clone N418, Cat#117310, Lot#B206713), anti-IL7Rα (BioLegend, clone SB/199, Cat#121112, Lot#B189668), anti-CD16/32 (BioLegend, clone 93, Cat#101324, Lot#B250025), anti-CD150 (BioLegend, clone TC15–12F12.2, Cat#115922, Lot#B220585), anti-cKit (BioLegend, clone 2B8, Cat#105814, Lot#B252918), anti-CD135 (BioLegend, clone A2F10, Cat#135310, Lot#B234045), anti-CD48 (BioLegend, clone HM48–1, Cat#103426, Lot#B236445), anti-Sca1 (BioLegend, clone D7, Cat#108126, Lot#B234288), anti-CD8 (BD Bioscience, clone 53–6.7, Cat#553035, Lot#2296946), anti-CD4 (BioLegend, clone GK1.5, Cat#100428, Lot#B237336), anti-SiglecF (BD Pharmingen, clone E50–2440, Cat#562680, Lot#7054789), anti-CXCR4 (Invitrogen, clone 2B11, Cat#12–9991-81, Lot#B251481), anti-CXCR2 (BioLegend, clone SA044G4, Cat#149307, Lot#B251481), anti-BrdU (eBioscience, clone BU20A, Cat#17–5071-42, Lot#4319920).

    Techniques: Expressing, Flow Cytometry, Cytometry, Mouse Assay